title: Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.
abstract: OBJECTIVE
  Growth factor receptor-binding protein 14, a new member of noncatalytic adaptor proteins family, has been shown to be upregulated in breast cancer. We investigated the prognostic value of growth factor receptor-binding protein 14 expression in breast cancer patients treated with neoadjuvant chemotherapy.
  
  
  METHODS
  Primary breast cancer specimens were taken from locally advanced breast cancer patients in a Phase II clinical trial of neoadjuvant chemotherapy and the expression pattern of growth factor receptor-binding protein 14 was determined by immunohistochemistry. Kaplan-Meier analysis and Cox regression model were used to assess disease-free and overall survival, according to the expression of growth factor receptor-binding protein 14 in tumor cells.
  
  
  RESULTS
  Our result showed that growth factor receptor-binding protein 14 was highly expressed in 23.1% of breast cancer sections, and high expression of growth factor receptor-binding protein 14 was significantly associated with better disease-free (P = 0.016, hazard ratio 0.07, 95% confidence interval 0.06-0.08) and overall survival (P = 0.004, hazard ratio 0.02, 95% confidence interval 0.02-0.03), compared with the low-expression group. Multivariate analysis indicated that high expression of growth factor receptor-binding protein 14 was an independent good prognostic factor for both disease-free (P = 0.04, hazard ratio 0.37, 95% confidence interval 0.14-0.98) and overall survival (P = 0.03, hazard ratio 0.11, 95% confidence interval 0.10-0.82).
  
  
  CONCLUSIONS
  High expression of growth factor receptor-binding protein 14 in breast cancer cells may help to identify low-risk patients for additional therapies after neoadjuvant chemotherapy.
authors.affiliation: *Department of Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, No.197, 2nd Ruijin Road, Huangpu District, Shanghai 200025, PR China. breastcancer@126.com.
authors.forename: Ou
authors.initials: O
authors.lastname: Huang
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.forename: Xi
authors.initials: X
authors.lastname: Zhang
authors.forename: Zuoquan
authors.initials: Z
authors.lastname: Xie
authors.forename: Xiaosong
authors.initials: X
authors.lastname: Chen
authors.forename: Jiayi
authors.initials: J
authors.lastname: Wu
authors.forename: Hongchun
authors.initials: H
authors.lastname: Liu
authors.forename: Kunwei
authors.initials: K
authors.lastname: Shen
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000032:analysis*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People / Q000706:statistics & numerical data; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D002681:China / Q000453:epidemiology; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy / Q000379:methods*; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D015854:Up-Regulation
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; C099655:GRB14 protein, human
keywords: breast cancer; grb14; locally advanced; neoadjuvant chemotherapy; prognosis